Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Neprilysin inhibitors cause an increase in levels of natriuretic peptides, which are important in maintaining fluid and sodium balance through natriuresis, diuresis, and vasodilation. This reduces blood pressure and effectively treats heart failure. Neprilysin can be used in combination with other medications to enhance the treatment of heart failure. Thus, anti-neprilysin medications are used for treatment of hypertension, heart failure, renal diseases, and others. Entresto is the only brand available in the market manufactured by Novartis International AG. Entresto is combination of sacubitril/valsartan that is the drug combination of angiotensin receptor neprilysin inhibitor (ARNI) respectively. Sacubitril/valsartan is used in place of an angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blocker (ARB) and in conjunction treatment when it is not working for heart disease patients.

Anti-Neprilysin Market - Impact of Coronavirus (Covid-19) Pandemic

The pandemic of COVID-19 has significantly augmented demand for several drugs. The spread of coronavirus is also negatively impacting the sales of companies, whose product demand highly depend on selective disease treatments such as anti-neprilysin, which is majorly used for treatment of heart diseases. Furthermore, cardiovascular disease patients are highly at risk of being affected by COVID-19 infection due to fragile heart conditions. The COVID-19 infects the lungs, drop blood oxygen levels at first and secondly, the inflammatory effects of the virus itself will cause the blood pressure to drop. In such cases, the heart must beat faster and harder to supply oxygen to major organs due to which the survival rates of individuals with ailing heart conditions become very less even with proper medications.

The anti-neprilysin market is estimated to be valued at US$ 1,109.25 million in 2020 and is expected to exhibit a CAGR of 4.6% during the forecast period (2020-2027).

Figure 1: Anti-Neprilysin Market Share (%) Analysis, By Technology, 2027

Anti-Neprilysin  | Coherent Market Insights

Increasing prevalence of cardiovascular disorders and product approvals are expected to boost growth of the anti-neprilysin market

Anti-neprilysin drug Entresto is expected to be useful to treat other diseases such as hypertension, Alzheimer’s disease, stroke, atrial fibrillation, renal diseases, and some other diseases are under research with anti-neprilysin treatment. Therefore, increasing prevalence of such diseases is expected to boost the anti-neprilysin market growth over the forecast period. For instance, according to the World Health Organization (WHO) report of September 2019, around 1.13 billion people worldwide suffered from hypertension, most living in low- and middle-income countries in 2019. Moreover, rising prevalence of hypertension increases the risk of heart attack, stroke, and kidney damage, as well as other health problems.

Furthermore, the anti-neprilysin market is expected to witness significant growth in the near future, owing to increasing product approvals by regulatory bodies. For instance, in February 2015, Novartis International AG announced that the U.S. Food and Drug Administration (FDA) granted priority review for LCZ696, an investigational medicine for the treatment of heart failure with reduced ejection fraction (HFrEF). The designation is intended to accelerate the review of therapies that offer a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious condition.

Anti-Neprilysin Market - Restraints

However, frequent drug recalls is expected to hamper the anti-neprilysin market growth over the forecast period. Frequent drug recalls are caused due to various reasons such as faulty packaging and inconsistency in formation among others. For instance, in July 2018, Novartis issued a voluntary recall of Entresto Hospital Unit Dose (HUD) tablets. This recall was issued, as the packaging of these products were not child-resistant, which could pose a risk of harm if the tablets are swallowed by children.

request-sample

Anti-Neprilysin Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 1,109.25 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 4.6% 2027 Value Projection: US$ 1,665.72 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Sacubitril, TD-0714, STR-324, PL-265, LHW-090.
  • By Indication: Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer’s Disease, Others.
  • By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Bioprojet SCR, Novartis International AG, Pharmaleads SA, Theravance Biopharma Inc., Cipla Limited, and Oceanic Pharmachem Pvt. Ltd.

Growth Drivers:
  • Increasing prevalence of cardiovascular disorders
  • The increasing number of product approvals and launches
Restraints & Challenges:
  • Drug recalls

Anti-Neprilysin Market – Regional Analysis

North America accounted for the largest share in the anti-neprilysin market in 2019, owing to definitive agreements between companies in the region. For instance, in February 2016, Cigna Corporation and Aetna Inc. entered into an outcome-based studies agreement with the pharmaceutical company Novartis for the drug Entresto, which was approved by the U.S. Food and Drug Administration for the treatment of heart failure with reduced ejection fraction. In this agreement, Cigna's pharmacists and nurses are involved in providing focused clinical care, which includes monitoring a customer’s medication adherence, side effects, and drug interactions, reviewing lab values, and collaborating with customers’ physicians when adjustments are needed.

Furthermore, the increasing number of clinical trials of anti-neprilysin drugs are expected to accelerate the anti-neprilysin market growth in the near future. For instance, in June 2017, Pharmaleads, a France-based pharmaceutical company, announced positive results in a first Phase I trial for its DENKI peptide PL265 to treat chronic neuropathic pain. Moreover, the biotech company announced that its second clinical stage peptide, PL265, has successfully cleared a Phase I single-ascending dose (SAD) trial, allowing the company to move its compound towards the next stage of clinical development.

Figure 2: Anti-Neprilysin Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

Anti-Neprilysin  | Coherent Market Insights

Anti-Neprilysin Market - Competitive Landscape

Key players operating in the anti-neprilysin market include Bioprojet SCR, Novartis International AG, Pharmaleads SA, Theravance Biopharma Inc., Cipla Limited, and Oceanic Pharmachem Pvt. Ltd.

Anti-neprilysin drugs are majorly used for acute heart failure, cancer pain, hypertension, Alzheimer’s disease, and other diseases. Most commonly used anti-neprilysin is Sacubitril/valsartan, which is sold under the brand name, Entrest. It consists of neprilysin inhibitor, sacubitril and the angiotensin receptor blocker, valsartan. Entrest was first manufactured by Novartis International AG in 2015. After the arrival of this drug in the market, there has been a reduction in the rate of cardiovascular deaths and hospitalization related to heart failure. Due to the increasing prevalence of heart failure, the U.S.FDA granted fast track designation to Entresto in 2015, which supports FDA’s efforts to facilitate the development and expedite the review of drugs to treat serious or life-threatening conditions and meet unmet medical needs of patients.

Market Dynamics

The increasing prevalence of acute heart failure is expected to highly contribute to the anti-neprilysin market growth over the forecast period. For instance, according to the data published in the Continuing Cardiology Education Journal in 2017, heart failure (HF) is a major public health problem, affecting a total of 26 million people worldwide in 2014. Furthermore, according to the American Heart Association report, the prevalence of acute heart failure in the U.S. in 2012 was 5.7 million, representing 2.2% of the population. The projection is that HF prevalence will increase by 46% by 2030, resulting in over 8 million adults with HF in the U.S. in 2030.

However, the anti-neprilysin market growth is expected to be hampered over the forecast period, owing to the side effects and adverse effects associated with anti-neprilysin drugs. For instance, the drug called Entresto (sacubitril and valsartan), a combination of a neprilysin inhibitor and an angiotensin II receptor blocker, might exhibit serious side effects such as low blood pressure (hypotension), high blood potassium (hyperkalemia), cough, dizziness, and kidney (renal) failure. Such side effects can create life-threating conditions if not consumed under expert supervision.

Key features of the study:

  • This report provides in-depth analysis of the global anti-neprilysin market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global anti-neprilysin market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Bioprojet SCR, Novartis International AG, Pharmaleads SA, Theravance Biopharma Inc., Cipla Limited, and Oceanic Pharmachem Pvt. Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global anti-neprilysin market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for anti-neprilysin market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global Anti-Neprilysin Market, By Drug Type:
    • Sacubitril
    • TD-0714
    • STR-324
    • PL-265
    • LHW-090
    • Others
  • Global Anti-Neprilysin Market, By Indication:
    • Acute Heart Failure
    • Cancer Pain
    • Hypertension
    • Alzheimer’s Disease
    • Others
  • Global Anti-Neprilysin Market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Anti-Neprilysin Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug Type:
        • Sacubitril
        • TD-0714
        • STR-324
        • PL-265
        • LHW-090
        • Others
      • By Indication:
        • Acute Heart Failure
        • Cancer Pain
        • Hypertension
        • Alzheimer’s Disease
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug Type:
        • Sacubitril
        • TD-0714
        • STR-324
        • PL-265
        • LHW-090
        • Others
      • By Indication:
        • Acute Heart Failure
        • Cancer Pain
        • Hypertension
        • Alzheimer’s Disease
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug Type:
        • Sacubitril
        • TD-0714
        • STR-324
        • PL-265
        • LHW-090
        • Others
      • By Indication:
        • Acute Heart Failure
        • Cancer Pain
        • Hypertension
        • Alzheimer’s Disease
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug Type:
        • Sacubitril
        • TD-0714
        • STR-324
        • PL-265
        • LHW-090
        • Others
      • By Indication:
        • Acute Heart Failure
        • Cancer Pain
        • Hypertension
        • Alzheimer’s Disease
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug Type:
        • Sacubitril
        • TD-0714
        • STR-324
        • PL-265
        • LHW-090
        • Others
      • By Indication:
        • Acute Heart Failure
        • Cancer Pain
        • Hypertension
        • Alzheimer’s Disease
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug Type:
        • Sacubitril
        • TD-0714
        • STR-324
        • PL-265
        • LHW-090
        • Others
      • By Indication:
        • Acute Heart Failure
        • Cancer Pain
        • Hypertension
        • Alzheimer’s Disease
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • Bioprojet SCR*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Novartis AG
  • Pharmaleads SA
  • Theravance Biopharma Inc.
  • Cipla Limited
  • Oceanic Pharmachem Pvt. Ltd.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Regulatory Scenario
    • Reimbursement Scenario
    • New Product Launches/Approvals
    • Mergers & Acquisitions
    • Porter’s Analysis
    • PEST Analysis
  4. Global Anti-Neprilysin Market COVID-19 Impact Analysis
    • Pre-COVID Market Analysis
    • Post – COVID Market Analysis
    • Strategies
  5. Global Anti-Neprilysin Market, By Drug Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Sacubitril
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • TD-0714
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • STR-324
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • PL-265
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • LHW-090
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Anti-Neprilysin Market, By Indication, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Acute Heart Failure
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Cancer Pain
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Hypertension
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Alzheimer’s Disease
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Anti-Neprilysin Market, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  8. Global Anti-Neprilysin Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  9. Competitive Landscape
    • Company Profiles
      • Bioprojet SCR
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pharmaleads SA
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Theravance Biopharma Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Cipla Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Oceanic Pharmachem Pvt. Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 32 market data tables and 34 figures on "Global Anti-Neprilysin Market” - Forecast to 2027”

Frequently Asked Questions

The CAGR of the anti-neprilysin market is 4.6% during the forecast period (2020-2027).
The value of anti-neprilysin market is estimated to be US$ 1,109.25 million in 2020.
The prominent players in the global anti-neprilysin market include Bioprojet SCR, Novartis International AG, Pharmaleads SA, Theravance Biopharma Inc., Cipla Limited, and Oceanic Pharmachem Pvt. Ltd.
The anti-neprilysin market is expected to be valued at US$ 1,665.72 million in 2027.
North America is the major region in the anti-neprilysin market.
The increasing prevalence of cardiovascular disorders, and the increasing number of product approvals and launches are expected to drive growth of the anti-neprilysin market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner